{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:22:36Z","timestamp":1783477356073,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejps.2021.105913","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T01:21:51Z","timestamp":1623892911000},"page":"105913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7111-7837","authenticated-orcid":false,"given":"Jennifer J","family":"Bonner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor N","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4753","authenticated-orcid":false,"given":"Martin J","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105913_bib0001","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1124\/dmd.114.058099","article-title":"Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations","volume":"42","author":"Abduljalil","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2021.105913_bib0002","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S2213-8587(14)70142-1","article-title":"Diagnosis and management of adrenal insufficiency","volume":"3","author":"Bancos","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejps.2021.105913_bib0003","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/gut.27.8.886","article-title":"Transit of pharmaceutical dosage forms through the small intestine","volume":"27","author":"Davis","year":"1986","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2021.105913_bib0004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/j.1552-4604.1991.tb01906.x","article-title":"Pharmacokinetics and bioavailability of hydrocortisone","volume":"31","author":"Derendorf","year":"1991","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105913_bib0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40262-012-0022-9","article-title":"Optimal sampling times for a drug and its metabolite using SIMCYP((R)) simulations as prior information","volume":"52","author":"Dumont","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2021.105913_bib0006","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1210\/jc.2012-2102","article-title":"Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia","volume":"97","author":"Finkielstain","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2021.105913_bib0007","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrendo.2013.239","article-title":"Treatment and health outcomes in adults with congenital adrenal hyperplasia","volume":"10","author":"Han","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejps.2021.105913_bib0008","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","article-title":"Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance","volume":"2","author":"Jamei","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.ejps.2021.105913_bib0009","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"Jamei","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2021.105913_bib0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1460-9592.2010.03323.x","article-title":"Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice","volume":"21","author":"Johnson","year":"2011","journal-title":"Paediatr. Anaesth."},{"key":"10.1016\/j.ejps.2021.105913_bib0011","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","article-title":"Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children","volume":"45","author":"Johnson","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2021.105913_bib0012","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/bdd.1899","article-title":"Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents","volume":"35","author":"Johnson","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2021.105913_bib0013","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105913_bib0054","first-page":"1","article-title":"Bioavailability of oral hydrocortisone corrected for binding proteins and measured by LC-MS\/MS using serum cortisol and salivary cortisone","volume":"10","author":"Johnson","year":"2018","journal-title":"J Bioequiv"},{"key":"10.1016\/j.ejps.2021.105913_bib0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/EJE-16-0948","article-title":"Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia","volume":"176","author":"Karunasena","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejps.2021.105913_bib0014","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/clpt.2012.19","article-title":"Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials","volume":"91","author":"Leong","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2021.105913_bib0015","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1208\/s12248-014-9640-5","article-title":"Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model","volume":"16","author":"Li","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2021.105913_bib0016","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2014-3809","article-title":"A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia","volume":"100","author":"Mallappa","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2021.105913_bib0051","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40262-017-0575-8","article-title":"Predicting cortisol exposure from paediatric hydrocortisone formulation using a semi-mechanistic pharmacokinetic model established in healthy adults","volume":"57","author":"Melin","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejps.2021.105913_bib0017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/cen.13969","article-title":"The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing","volume":"91","author":"Melin","year":"2019","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.ejps.2021.105913_bib0018","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(05)66736-0","article-title":"Congential adrenal hyperplasia","volume":"365","author":"Merke","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2021.105913_bib0019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.dmpk.2017.11.314","article-title":"Quantitative analysis of elevation of serum creatinine via renal transporter inhibition by trimethoprim in healthy subjects using physiologically-based pharmacokinetic model","volume":"33","author":"Nakada","year":"2018","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2021.105913_bib0020","doi-asserted-by":"crossref","first-page":"e1433","DOI":"10.1210\/clinem\/dgaa626","article-title":"A Prospective Study Of Children 0-7 Years With Cah And Adrenal Insufficiency Treated With Hydrocortisone Granules","volume":"106","author":"Neumann","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2021.105913_bib0021","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EJE-17-0248","article-title":"Quality of compounded hydrocortisone capsules used in the treatment of children","volume":"177","author":"Neumann","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejps.2021.105913_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen.13447","article-title":"Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and childrens under 6 years of age with adrenal insufficiency","volume":"88","author":"Neumann","year":"2018","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.ejps.2021.105913_bib0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2017.05.043","article-title":"Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin","volume":"106","author":"Olafuyi","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105913_bib0053","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jps.2600730726","article-title":"Bioavailability of hydrocortisone from commercial 20-mg tablets","volume":"73","author":"Patel","year":"1984","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejps.2021.105913_bib0024","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/archdischild-2015-309538","article-title":"Is physiological glucocorticoid replacement important in children?","volume":"102","author":"Porter","year":"2017","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejps.2021.105913_bib0025","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1124\/dmd.115.068031","article-title":"Physiologically based pharmacokinetic modeling in pediatric oncology drug development","volume":"44","author":"Rioux","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2021.105913_bib0026","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105913_bib0027","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-014-0140-7","article-title":"A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data","volume":"53","author":"Salem","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2021.105913_bib0028","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/psp4.12203","article-title":"Quantitative modeling and simulation in PMDA: a Japanese regulatory perspective","volume":"6","author":"Sato","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105913_bib0029","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2021.105913_bib0030","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/jps.2600711029","article-title":"Effect of dose size on the pharmacokinetics of oral hydrocortisone suspension","volume":"71","author":"Toothaker","year":"1982","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105913_bib0031","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jps.2600710522","article-title":"Oral hydrocortisone pharmacokinetics: a comparison of fluorescence and ultraviolet high-pressure liquid chromatography assays for hydrocortisone in plasma","volume":"71","author":"Toothaker","year":"1982","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105913_bib0032","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF01062332","article-title":"Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression","volume":"10","author":"Toothaker","year":"1982","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejps.2021.105913_bib0033","doi-asserted-by":"crossref","unstructured":"Walker, B., Seckl, J., 2001. Cortisol Metabolism, in: Bjorntorp, P. (Ed.), International Textbook of Obesity. John Wiley and Sons Ltd, pp. 241-268.","DOI":"10.1002\/0470846739.ch18"},{"key":"10.1016\/j.ejps.2021.105913_bib0034","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.metabol.2017.02.005","article-title":"Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial","volume":"71","author":"Werumeus Buning","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.ejps.2021.105913_bib0035","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/cen.12316","article-title":"An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure","volume":"80","author":"Whitaker","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ejps.2021.105913_bib0036","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1210\/jc.2014-4060","article-title":"Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with congenital adrenal insufficiency","volume":"100","author":"Whitaker","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2021.105913_bib0037","doi-asserted-by":"crossref","first-page":"E970","DOI":"10.1152\/ajpendo.00495.2006","article-title":"Sexual dimorphism in cortisol secretion starts after age 10 in healthy children: urinary cortisol metabolite excretion rates during growth","volume":"293","author":"Wudy","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721002141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721002141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:58:22Z","timestamp":1760529502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721002141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":41,"alternative-id":["S0928098721002141"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105913","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105913"}}